| Page 1943 | Kisaco Research
NY Summit 2017: Post show report
NY Summit 2017: Post show report
NY Summit 2017: Post show report

Thank you for Registering

We're looking forward to delivering an exceptional onsite experience for you. Please feel free to reach out to the events team with any questions you may have leading up to the event and we'll be sure to address them for you.

Please reach out to [email protected] or call +44 (0)20 3696 2922 for more information.

Thank you for Registering

We're looking forward to delivering an exceptional onsite experience for you. Please feel free to reach out to the events team with any questions you may have leading up to the event and we'll be sure to address them for you.

Please reach out to [email protected] or call +44 (0)20 3696 2922 for more information.

Thank you for Registering

We're looking forward to delivering an exceptional onsite experience for you. Please feel free to reach out to the events team with any questions you may have leading up to the event and we'll be sure to address them for you.

Please reach out to [email protected] or call +44 (0)20 3696 2922 for more information.

 

Mathieu Castex, Ph.D

R&D Director
Lallemand

Mathieu Castex has been with Lallemand Animal Nutrition for close to a decade, committed since the beginning of his career to developing new applications for probiotics and yeast fractions applied to livestock and companion animals.

Mathieu Castex, Ph.D

R&D Director
Lallemand

Mathieu Castex, Ph.D

R&D Director
Lallemand

Mathieu Castex has been with Lallemand Animal Nutrition for close to a decade, committed since the beginning of his career to developing new applications for probiotics and yeast fractions applied to livestock and companion animals.

Mathieu is based at Lallemand Animal Nutrition’s headquarters near Toulouse, France, and is acting as head of the R&D department. He manages a multicultural team of microbiologists, physiologists and nutritionists conducting research projects aiming at developing and/or documenting the effects of microbial based feed additives on the performance and health of livestock. Particular efforts are dedicated to research aiming at revealing the biological mechanisms involved in the interactions between the animal (the host) and its microbiota, and how those interactions drive animal feed efficiency and health. Mathieu also manages the Lallemand Centers of Excellence, research platforms across Europe and North America dedicated to the understanding of microbial ecosystems , product development and investigation of their modes of action, and he is also in charge of a wide partnership network with research institutes across the world.

 

Mathieu holds a Master in animal sciences and a PhD in microbiology and physiology of nutrition applied to aquatic organisms from AgroParisTech (France). After a period at IFREMER (French Institute of Marine Science), he developed transversal experiences in terms of marketing, business development, bioprocessing and Research and Development. His major research interests are about the understanding of the complex interactions between the animal and its intestinal microbiota resulting in responses at the local (Gastrointestinal tract) and systemic levels. 

 

 

 

Anne Chauder

Chief Executive Officer
DOMES PHARMA Group

Anne Chauder is the third generation at the head of a French independent family group of 350 employees, pioneer in animal health.  In 2003, after studying Management, she chose to bring her skills to the family business. She became Executive Director in 2012 and then C.E.O in 2016  with aims to prepare the Dômes Pharma Group to address its third great evolution: digitalization and internationalization.

Anne Chauder

Chief Executive Officer
DOMES PHARMA Group

Anne Chauder

Chief Executive Officer
DOMES PHARMA Group

Anne Chauder is the third generation at the head of a French independent family group of 350 employees, pioneer in animal health.  In 2003, after studying Management, she chose to bring her skills to the family business. She became Executive Director in 2012 and then C.E.O in 2016  with aims to prepare the Dômes Pharma Group to address its third great evolution: digitalization and internationalization.

 

Vince Wacher

Strategy and Development
Synthetic Biologics, Inc

Vince Wacher

Strategy and Development
Synthetic Biologics, Inc

Vince Wacher

Strategy and Development
Synthetic Biologics, Inc